FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387362479> ?p ?o ?g. }

• W4387362479 abstract "Abstract Disclosure: L. WingChing: None. X. Khor: None. F. Carter: None. Q. Ashcroft: None. V. Chandrabalan: None. P. M Joseph: None. Authors: Li Wing Ching, Xiao Ying Khor, Frederick Carter, Ashcroft Quinta, Vishnu Chandrabalan, Joseph Pappachan. Background: Relapse of Graves’ disease occurs in ≈50% of cases after the antithyroid pharmacotherapy. Identifying risk factors associated with relapse is crucial for planning treatment including radioactive iodine (RAI) ablation as well as to inform patients of probable clinical outcome following such treatment. Aims: (1) To identify the factors associated with relapse of Graves’ disease when the condition is first diagnosed. (2) To characterise the clinical outcomes and re-relapse rates after RAI treatment. Methods: Retrospective study of patients treated for Graves’ disease (with positive TSH-receptor antibodies [TRAb] &gt;1.0 IU/L) between April 2004 and May 2021 at Lancashire Teaching Hospitals NHS Trust, UK. Demographic, clinical, laboratory, and treatment data were retrieved from prospectively maintained electronic health records. Data retrieved included known factors associated with high risk of relapse including markedly raised thyroid hormone (Free T4 [FT4] and/or Free T3 [FT3]), and TRAb levels. Outcome data after treatment was also analysed including the effects of RAI therapy such as hypothyroidism and time to its development, failure rate of first dose of RAI and its management. Results: Out of 1450 patients with Graves’ disease, 188 cases with meaningful study data receiving RAI ablation during the study period were analysed. The following factors (median (interquartile range/IQR) of relapsed vs non-relapsed) were associated with relapse requiring RAI ablation: TRAb levels - 10.3 (4.8-20.9) vs 5.1 (2.0-12.4) IU/L; p&lt;0.001, FT4 - 56.7 (39.3 - 73.0) vs 42.6 (30.9-62.4) pmol/L; p&lt;0.01, and FT3 - 24.4 (13.8 - 33.6) vs 16.2 (10.8-26.5) pmol/L; p=0.03. The median age at RAI ablation therapy was 48 (IQR 39-57.3) years with a female preponderance (140 [74.5%] cases). Radioactive Iodine-131 (131I) 555 MBq was used for treatment in all cases. 172 (91.5%) cases developed post-RAI hypothyroidism at a median follow up period of 3 (IQR: 2-11) months. RAI ablation failure occurred in 20 (10.6%) cases of whom 12 (60%) cases were successfully managed by RAI re-ablation, 5 (25%) cases preferred antithyroid pharmacotherapy, one (5%) underwent subtotal thyroidectomy and 2 (10%) cases refused treatment. Conclusions: Graves’ disease cases with high median levels of TRAb ≥10.3 IU/L, FT4 ≥56.7 pmol/L and/or FT3 ≥24.4 pmol/L at initial presentation are at high risk of relapse. RAI ablation should be offered to such patients as first-line treatment at initial presentation of the disease. Hypothyroidism occurs after RAI ablation in ≈92%. Chance of treatment failure with first RAI ablation procedure is only ≈11%. Presentation Date: Saturday, June 17, 2023" @default.
• W4387362479 created "2023-10-06" @default.
• W4387362479 creator A5002780342 @default.
• W4387362479 creator A5006044370 @default.
• W4387362479 creator A5060633510 @default.
• W4387362479 creator A5066916827 @default.
• W4387362479 creator A5074800817 @default.
• W4387362479 creator A5093007385 @default.
• W4387362479 date "2023-10-01" @default.
• W4387362479 modified "2023-10-06" @default.
• W4387362479 title "SAT469 Risk Factors for Relapse in Graves’ Disease and the Clinical Outcomes of Radioactive Iodine Treatment in Relapsed Cases" @default.
• W4387362479 doi "https://doi.org/10.1210/jendso/bvad114.1943" @default.
• W4387362479 hasPublicationYear "2023" @default.
• W4387362479 type Work @default.
• W4387362479 citedByCount "0" @default.
• W4387362479 crossrefType "journal-article" @default.
• W4387362479 hasAuthorship W4387362479A5002780342 @default.
• W4387362479 hasAuthorship W4387362479A5006044370 @default.
• W4387362479 hasAuthorship W4387362479A5060633510 @default.
• W4387362479 hasAuthorship W4387362479A5066916827 @default.
• W4387362479 hasAuthorship W4387362479A5074800817 @default.
• W4387362479 hasAuthorship W4387362479A5093007385 @default.
• W4387362479 hasBestOaLocation W43873624791 @default.
• W4387362479 hasConcept C119060515 @default.
• W4387362479 hasConcept C126322002 @default.
• W4387362479 hasConcept C167135981 @default.
• W4387362479 hasConcept C187212893 @default.
• W4387362479 hasConcept C2776652619 @default.
• W4387362479 hasConcept C2778707442 @default.
• W4387362479 hasConcept C2779134260 @default.
• W4387362479 hasConcept C2908975369 @default.
• W4387362479 hasConcept C526584372 @default.
• W4387362479 hasConcept C71924100 @default.
• W4387362479 hasConceptScore W4387362479C119060515 @default.
• W4387362479 hasConceptScore W4387362479C126322002 @default.
• W4387362479 hasConceptScore W4387362479C167135981 @default.
• W4387362479 hasConceptScore W4387362479C187212893 @default.
• W4387362479 hasConceptScore W4387362479C2776652619 @default.
• W4387362479 hasConceptScore W4387362479C2778707442 @default.
• W4387362479 hasConceptScore W4387362479C2779134260 @default.
• W4387362479 hasConceptScore W4387362479C2908975369 @default.
• W4387362479 hasConceptScore W4387362479C526584372 @default.
• W4387362479 hasConceptScore W4387362479C71924100 @default.
• W4387362479 hasIssue "Supplement_1" @default.
• W4387362479 hasLocation W43873624791 @default.
• W4387362479 hasOpenAccess W4387362479 @default.
• W4387362479 hasPrimaryLocation W43873624791 @default.
• W4387362479 hasRelatedWork W2036521104 @default.
• W4387362479 hasRelatedWork W2057252846 @default.
• W4387362479 hasRelatedWork W2351921826 @default.
• W4387362479 hasRelatedWork W2358633025 @default.
• W4387362479 hasRelatedWork W2359871188 @default.
• W4387362479 hasRelatedWork W2392107066 @default.
• W4387362479 hasRelatedWork W2392543696 @default.
• W4387362479 hasRelatedWork W3029171990 @default.
• W4387362479 hasRelatedWork W3201851107 @default.
• W4387362479 hasRelatedWork W3208354384 @default.
• W4387362479 hasVolume "7" @default.
• W4387362479 isParatext "false" @default.
• W4387362479 isRetracted "false" @default.
• W4387362479 workType "article" @default.